Oral Dissolving Strip vs Capsule: The Bioavailability Gap

By Jack Zheng, MS Pharmacy — Founder of MIHIYO Labs

Summary

An oral dissolving strip (ODS) and a capsule deliver the same active by very different routes, and the bioavailability gap depends on the compound. A capsule must disintegrate in the stomach, empty into the intestine, and survive hepatic first-pass before reaching circulation; an ODS dissolves on the oral mucosa and can deliver part of the dose straight into systemic blood. For caffeine the difference is mostly onset; for melatonin a sublingual route raises Cmax and AUC over a swallowed tablet (Bartoli et al., 2023). MIHIYO Labs uses the ODS format when route, not dose size, is the limiting variable.

How does an oral dissolving strip compare with a capsule for absorption?

The short answer: a capsule and an oral dissolving strip can both deliver the same active to the bloodstream, but they get there by different routes, and the size of the bioavailability advantage of the strip depends entirely on how much the liver destroys the compound on first pass. For a molecule with near-complete oral bioavailability — caffeine is the cleanest example — the routes converge on similar total exposure, and the ODS advantage is onset, not amount. For a molecule with heavy first-pass loss — melatonin is the cleanest example — the routes diverge, and a sublingual or buccal ODS can recover a meaningful fraction of dose that a swallowed capsule loses.

Throughout this article I use "oral dissolving strip (ODS)" to mean a thin polymer film placed against the inner cheek or under the tongue, which dissolves in saliva over roughly 30–90 seconds and releases its active onto the oral mucosa. After the first mention I shorten to ODS.

Why capsules add steps before absorption

A swallowed capsule does not "go to the bloodstream." It goes through a sequence of physical and biochemical steps, each of which adds time, variability, or loss before any drug reaches circulation.

Step 1 — Disintegration. The gelatin or HPMC shell must rupture in the stomach. Across in vivo gamma-scintigraphy studies, hard gelatin capsules in healthy fasted volunteers begin disintegrating around 5–10 minutes after ingestion, with significant individual range (Wilding et al., 2000; Digenis et al., 2000). Food prolongs this: mean in vivo disintegration is roughly 7 minutes fasted versus 11 minutes fed in some scintigraphic series (Digenis et al., 2000). Cross-linked or stressed gelatin can push disintegration out further still.

Step 2 — Gastric emptying. Once the contents are dispersed, the active still has to leave the stomach. In the fasted state, gastric emptying varies from about 15 minutes to more than 3 hours depending on the interdigestive migrating motor complex (MMC) phase at the time of ingestion (Sjögren et al., 2014). A meal pushes emptying further out — often well over an hour. This is the single largest source of inter-individual variability in oral absorption rate.

Step 3 — Intestinal absorption. Most absorption then occurs across the small-intestinal mucosa, which is large in surface area and well-vascularized but drains into the portal vein.

Step 4 — Hepatic first-pass metabolism. Everything absorbed from the gut passes through the liver before reaching the systemic circulation. For compounds with a high hepatic extraction ratio — melatonin is the textbook example, with absolute oral bioavailability of only about 3–33% across studies (Harpsøe et al., 2015) — most of the dose is metabolized before it ever reaches the brain or peripheral target tissues. For compounds with low first-pass extraction, the loss is minimal.

The ODS route skips Steps 1–4 for whatever fraction of the dose absorbs across the oral mucosa. The buccal and sublingual mucosae are non-keratinized epithelia drained by veins that bypass the portal circulation and empty into the jugular system. The sublingual region is the most permeable of the oral mucosae — thinner and more vascularized than buccal — followed by buccal and then palatal (Squier, 1991). What does not absorb sublingually is eventually swallowed with saliva and then goes through the capsule route described above. So a real-world ODS dose is usually a blend: part mucosal, part GI.

What the bioavailability data shows

The spine of this comparison is the table below. Each row is a concrete pharmacological dimension where capsules and ODS measurably differ. Behind each row is a paragraph of mechanism.

Bioavailability — compound-dependent. This is the single most important point in the comparison, and it is the part most marketing copy gets wrong. For caffeine, oral bioavailability from a swallowed capsule is essentially complete: Blanchard & Sawers (Eur J Clin Pharmacol, 1983, PMID 6832208) measured absolute oral bioavailability near-complete in healthy adults (F ≈ 1.0), and a 2022 systematic PK analysis confirmed near-complete oral absorption across the literature (Grzegorzewski et al., Front Pharmacol, 2022). The total dose reaching the bloodstream from a caffeine capsule and a caffeine ODS is, to a first approximation, the same. For melatonin the picture is the opposite: the systematic review by Harpsøe et al. (Eur J Clin Pharmacol, 2015, PMID 26008214) found absolute oral bioavailability of roughly 9–33% across 22 PK studies, with extreme inter-individual variability driven by CYP1A2 activity, age, sex, and feeding. A 2023 crossover study (Bartoli/Ait Abdellah et al., Drugs in R&D, PMID 37438493) showed that an immediate-release sublingual melatonin spray produced an early, high plasma peak versus an oral prolonged-release tablet, consistent with partial bypass of first-pass metabolism.

Onset — favors ODS for both. Kamimori et al. (Int J Pharm, 2002, PMID 11839447) ran a double-blind randomized study of 84 healthy adults comparing caffeinated chewing gum, which keeps caffeine in sustained buccal contact, against caffeine capsules at 50, 100, and 200 mg. Mean Tmax for the gum was 44–80 minutes versus 84–120 minutes for the capsule, and the absorption rate constant (ka) was roughly twofold higher for the buccal route. The mechanism is straightforward: the gum/strip route bypasses gastric emptying, which is the slowest and most variable step in the capsule timeline.

GI exposure and first-pass. The buccal and sublingual mucosae drain into systemic veins, not the portal vein, so any fraction of dose absorbed mucosally avoids the liver until after distribution. For a compound the liver heavily metabolizes on first pass, this is the entire reason to use a mucosal route. For a compound with low hepatic extraction, this advantage collapses — the liver was not destroying much anyway.

Dose precision. Capsule absorption variability has two compounding sources: disintegration scatter (Digenis et al., J Pharm Sci, 2000, PMID 10888309, documented in vivo disintegration ranging from minutes to tens of minutes depending on cross-linking and formulation) and first-pass scatter (for high-extraction compounds, several-fold differences in delivered dose between individuals). An ODS shifts the dominant variability source to mucosal contact time, which the user controls more directly by placement and not chewing or rinsing.

Water requirement and swallowing burden. Schiele et al. (Eur J Clin Pharmacol, 2013, PMID 23052416) surveyed 1,051 primary-care patients in Germany and found that 37.4% reported difficulty swallowing tablets and capsules, with one in eleven reporting frequent difficulty. Prevalence rises further in older adults and patients with dysphagia. An ODS removes water and the swallow reflex from the dose-administration step entirely.

What this means for MIHIYO products

The decision to formulate a given active as an ODS rather than a capsule is, in my work, a compound-by-compound choice driven by the pharmacology, not a blanket "ODS is better" position.

For caffeine, the Energy-Focus ODS is designed around onset, not total bioavailability. Capsule caffeine eventually delivers the same total dose, but with Tmax in the 84–120 minute window (Kamimori et al., 2002). When the use case is early-morning alertness or pre-workout timing, that delay is the limiting variable. The ODS is engineered to maintain mucosal contact long enough for a meaningful fraction of dose to absorb buccally before the rest is swallowed — a faster, tighter peak. The argument for the strip here is not "more caffeine reaches your blood." It is "the caffeine that reaches your blood, reaches it sooner and more predictably." Our companion article on how fast caffeine strips actually work walks the Kamimori PK numbers in detail.

For melatonin, the Sleep-Support ODS is designed around dose precision and first-pass bypass. Oral melatonin loses 67–97% of dose to hepatic metabolism with extreme inter-individual scatter (Harpsøe et al., 2015), which is why a 5 mg capsule does not deliver 5 mg to the bloodstream — it delivers somewhere between roughly 0.15 mg and 1.65 mg depending on the person. A sublingual route partly recovers that loss (Bartoli et al., 2023), so a smaller labeled dose can hit the physiological serum-melatonin window without the variability and overshoot of a high-dose capsule. The reasoning behind why higher capsule doses do not produce stronger sleep onset effects is the subject of our melatonin strip dosage article.

Every citation in this article is on independent capsule, tablet, spray, or gum formulations studied by research groups outside MIHIYO Labs. We do not currently have a head-to-head human PK study comparing the MIHIYO ODS to a matched capsule. The pharmacological framework above is general; the specific PK numbers belong to the cited compounds and formulations.

Where capsules still make sense

Capsules are not a worse dosage form. They are the right form for a large set of compounds and clinical use cases, and being honest about that is part of the brand.

Compounds that need GI absorption or enteric protection. Fat-soluble vitamins, large-dose probiotics, enteric-coated enzymes, and any active intended to act locally in the gut belong in a capsule (often a softgel or delayed-release form), not on a strip.

Doses too large to fit a film. An ODS realistically carries milligram to low tens-of-milligram doses. A 500 mg amino acid load or a 1000 mg fish-oil dose does not physically fit. Capsules and softgels scale to multi-hundred-milligram loads in a single unit; films do not.

Compounds with low oral mucosal permeability. Highly hydrophilic or large-molecule actives — peptides above a few hundred Daltons, many sugars, most charged species — do not cross the oral mucosa efficiently. For these, putting them in a strip would not change bioavailability; the dose would simply be swallowed.

Sustained release. Prolonged-release formulations require a multi-hour erosion or diffusion profile that capsule and tablet matrices are designed for. An ODS, which dissolves in under two minutes, is fundamentally an immediate-release format.

Stability of moisture-sensitive actives. Some actives degrade in the high-humidity environment of an unsealed strip much faster than in a hermetic capsule. Formulation work can mitigate this, but it is a real constraint.

The honest version of the comparison is: for low-dose, lipophilic, high-first-pass actives where onset and dose precision matter, the ODS is the better tool. For high-dose, GI-dependent, or sustained-release applications, a capsule still wins.

The bottom line

For an oral dissolving strip vs capsule comparison, the bioavailability gap is not a fixed number — it is a function of the active. For caffeine and other near-complete-absorption compounds, both forms deliver essentially the same total dose, and the ODS advantage is onset and convenience. For melatonin and other high-first-pass compounds, the capsule loses most of the dose to hepatic metabolism, and a sublingual or buccal ODS recovers a meaningful fraction. Add in the 37% of adults who report difficulty swallowing pills (Schiele et al., 2013) and the case for offering an ODS option becomes one of practical access, not just pharmacology.

References

1. Blanchard J, Sawers SJ. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol. 1983;24(1):93-98. PMID: 6832208. <https://pubmed.ncbi.nlm.nih.gov/6832208/>

1. Kamimori GH, Karyekar CS, Otterstetter R, Cox DS, Balkin TJ, Belenky GL, Eddington ND. The rate of absorption and relative bioavailability of caffeine administered in chewing gum versus capsules to normal healthy volunteers. Int J Pharm. 2002;234(1-2):159-167. PMID: 11839447. <https://pubmed.ncbi.nlm.nih.gov/11839447/>

1. Grzegorzewski J, Bartsch F, Köller A, König M. Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing. Frontiers in Pharmacology. 2022;12:752826. PMID: 35280254. <https://pubmed.ncbi.nlm.nih.gov/35280254/>

1. Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-909. PMID: 26008214. <https://pubmed.ncbi.nlm.nih.gov/26008214/>

1. Bartoli AN, Marchesi N, Pascale A, Quaccini A, Govoni S. Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers. Drugs in R&D. 2023;23(3):257-265. PMID: 37438493. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10439092/>

1. Digenis GA, Sandefer EP, Page RC, Doll WJ, Gold TB, Darwazeh NB. Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture. Pharm Res. 2000;17(5):572-582. PMID: 10888309. <https://pubmed.ncbi.nlm.nih.gov/10888309/>

1. Sjögren E, Abrahamsson B, Augustijns P, Becker D, Bolger MB, Brewster M, et al. In vivo methods for drug absorption — Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. Eur J Pharm Sci. 2014;57:99-151. <https://pubmed.ncbi.nlm.nih.gov/24637348/>

1. Squier CA. The permeability of oral mucosa. Critical Reviews in Oral Biology and Medicine. 1991;2(1):13-32. <https://journals.sagepub.com/doi/10.1177/10454411910020010301>

1. Schiele JT, Quinzler R, Klimm HD, Pruszydlo MG, Haefeli WE. Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms. Eur J Clin Pharmacol. 2013;69(4):937-948. PMID: 23052416. <https://pubmed.ncbi.nlm.nih.gov/23052416/>

1. Lai F, Franceschini I, Corrias F, Sala MC, Cilurzo F, Sinico C, Pini E. A new melatonin oral delivery platform based on orodispersible films containing solid lipid microparticles. Int J Pharm. 2019;559:280-288. PMID: 30690132. <https://pubmed.ncbi.nlm.nih.gov/30690132/>